Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically proven grade I, II, or III follicular non-Hodgkin's lymphoma that
failed induction therapy

- Previously received no more than 2 high-dose chemotherapies before hematopoietic stem
cell transplantation

- Minimal disease state at day 100 to 6 months post-transplantation

- Lymph nodes smaller than 2 centimeters (cm)

- Less than 20% bone marrow involvement with lymphoma

- Uncertain complete remission, defined by greater than 75% reduction in the size
of the pre-transplantation mass not representing active disease

- Tissue sample safely accessible by biopsy, needle aspiration, or phlebotomy

- Must have adequate circulating lymphoma cells

PATIENT CHARACTERISTICS:

Age:

- Over 19

Performance status:

- Karnofsky greater than 70%

Life expectancy:

- Not specified

Hematopoietic:

- See Disease Characteristics

- Absolute neutrophil count greater than 1,000/mm^3*

- CD4+ count greater than 200/microliter* NOTE: *No restrictions if study vaccine
administered at 6 months after transplantation

Hepatic:

- Bilirubin less than 2.0 mg/dL (unless due to lymphomatous involvement)

- Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic
transaminase (SGPT) less than 2 times normal (unless due to lymphomatous involvement)

Renal:

- Creatinine no greater than 2.0 mg/dL

Other:

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for 6 months after study
participation

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- See Disease Characteristics

Chemotherapy:

- See Disease Characteristics

Endocrine therapy:

- Not specified

Radiotherapy:

- Not specified

Surgery:

- Not specified